/ /

LATEST

Welcome to the 2017 Glaucoma 360Adrienne Graves, PhD, and Andrew Iwach, MD, welcome attendees to Glaucoma 360 with their focus set on next year's conference, February 9, 2018 in San Francisco.
Novel device designed for pupil enlargement, stabilization in IFIS eyes
Novel device designed for pupil enlargement, stabilization in IFIS eyesWisconsin ophthalmologist Gerald P. Clarke, MD, has developed a new horseshoe-shaped dilator for use during cases of intraoperative floppy iris syndrome.
5 observations about corticosteroids for DME treatmentFindings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.
The latest ocular allergy treatments worth watchingProgress of ocular allergy treatment in 2017 starts with the fact that this is a mature therapeutic space, with a range of existing choices for clinicians and patients. Progression in therapies from artificial tears to antihistamines and mast cell stabilizers to topical steroids provides a suitable choice for most patients with ocular allergies.
How wide-field SS-OCT expands spectrum of normal peripheral retinaWide-field retinal imaging can be performed using a commercially available swept-source optical coherence tomography (SS-OCT) platform (DRI OCT Triton, Topcon) and only the internal fixation light for patient navigation provided detailed images of both normal and pathologic peripheral retinal findings.
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’A new hypersonic liquefaction vitrectomy system, called Vitesse PPVX (Bausch + Lomb), offers several advantages over currently available vitrector technology. The device received FDA 510k approval in April 2017.
How adaptive optics will change retinal imaging
How adaptive optics will change retinal imagingAdaptive optics could allow clinicians to monitor the progression of retinal diseases cell-by-cell, according to Jacque Duncan, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further study
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Spectacles saved our republicSometimes, we ophthalmologists—accustomed as we are to high-success rates with our therapeutic interventions—become inured to the impact our efforts can have on patients’ lives.
Three reasons for adopting DMEK in routine EK casesUsing the Descemet’s membrane endothelial keratoplasty (DMEK) procedure can produce better visual results and lower risk of rejection than using the previous methods (DLEK and DSAEK). The method has become easier to learn and use than in the past, and should be considered as the primary EK procedure for most routine cases of endothelial failure.

Poll

View Results